Business Wire

Theorem Solutions: Democratising Augmented, Mixed and Virtual Reality

Jaa

Theorem Solutions of Tamworth, UK, have launched a ‘Multi-Device’ Visualization Experience App for Augmented (AR), Mixed (MR) and Virtual Reality (VR) devices and markets.

The Visualization Experience app forms part of Theorem’s ‘Digital Realities’ product family, and has been specifically developed for users to engage and interact with their Engineering and Manufacturing data. It is one of the first to offer a single solution for all three different technologies in a single application.

Supported devices are:

  • Augmented Reality - Windows 10 and Android Tablets and Phones
  • Mixed Reality – Microsoft HoloLens
  • Virtual Reality - HTC Vive and Oculus Rift

Being Multi-Device, the application allows users to use the same data, in the same visualization application, on ALL of the different low-cost devices.

The app enables users to view, manipulate and interrogate CAD and PLM data using a combination of touch, hand gestures and voice controls-depending on the device- with each device suiting different use cases and scenarios.

“Today, we rely so much on technology - it simplifies our existence - but at the same time, we don’t fully utilize what’s available to us” observes Stuart Thurlby, CEO of Theorem Solutions.

“Some Engineering and Manufacturing processes are still not harnessing new technology or finding new ways of performing established tasks, but technology has evolved and needs to be embraced in order to keep up with, and be ahead of, the game. We see Augmented (AR), Mixed (MR) and Virtual Reality (VR) running on the new low cost devices to be that game-changer!”

With new low-cost devices and technologies for Augmented, Mixed and Virtual Reality emerging for the consumer markets, the natural progression into the commercial arena is beginning.

Existing Assets can be used.

“VR has been available for many years in the engineering and manufacturing space, but it has always come with an enormous price tag and only a few are in the ‘privileged’ position to fully be able to utilize the technology for visualization” Stuart comments, “but now the ability to use existing CAD and PLM assets in all of the latest devices without the price tag is actually a reality.”

How it works

The Theorem server architecture enables the CAD and PLM assets server to talk to other servers and prepare data so it can be streamed to a device. Existing CAD and PLM data assets from CATIA 3DEXPERIENCE, CATIA V5, CREO, Inventor, JT, NX, SolidWorks and STEP formats can be utilised.

Data is optimised and prepared for use once, and then delivers the same Visualization Experience across all supported platforms, saving money on data preparation, training and support.

Where does the technology come from?

These new devices and technologies are not coming from the Engineering and CAD/PLM industries, but from the gaming and social media industries.

Combining gaming technology with engineering CAD and PLM data in a single application creates an interactive user experience, and becomes even more powerful when combined with metadata from MES, ERP, CRM and IoT systems.

Theorem’s Visualization Experience is used for the Digital Twin area of the IoT, design reviews, Manufacturing Build, Quality Control, Service applications and training, and even sales & marketing, with the ability to tailor the experience to a specific use case.

The Visualization Experience integrates into existing workflows. Data can be dragged and dropped onto the server, populated via a PLM Release/Publish trigger or saved directly from CAD applications.

Theorem’s Visualization and Digital Reality products offer a key component to enable the ‘Visualization Pipeline’ and help to democratize AR, MR and VR throughout your organisation.

What Theorem are offering

“What Theorem are offering in the Visualization Experience is a framework, combined with consultancy, enabling you to build your own specific experiences.” Stuart Thurlby explains, “We have ensured that your data and device neutrality is there, which will protect your investment as this world changes. It is effectively future proofing your CAD and PLM assets”

“Ultimately, the Theorem Visualization Experience presents new and innovative ways of performing existing tasks, or creating entirely new processes and methods of delivery.”

For more information visit www.theorem.com/Digital-Realities

Supporting Images:

http://www.theorem.com/Digital-Realities/images/Digital-Realities.png

Notes to editor:

Theorem Solutions works with engineering and manufacturing companies to reduce the cost of project collaboration with their customers, suppliers and internal departments. The innovative and advanced data translation products and services provided also helps to protect the value of engineering data and the intellectual property it contains.

Contact information

For further press information or to request hi-resolution images contact:
Katharine Edmonds
Marketing Communications Assistant
Theorem Solutions
+44(0) 1827 305 350
katharine.edmonds@theorem.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 19:31Tiedote

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases19.11.2017 02:00Tiedote

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 21:20Tiedote

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 12:11Tiedote

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 19:20Tiedote

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 15:31Tiedote

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme